Brentuximab Vedotin and Combination Chemotherapy in Treating Patients with CD30-Positive Peripheral T-cell Lymphoma

Inclusion Criteria

• Documented informed consent of participant and/or legally authorized representative
• Agreement to allow the use of archival tissue from diagnostic tumor biopsies will be retrieved and submitted post-enrollment * If unavailable, exceptions may be granted with study principal investigator (PI) approval.
• Age: >= 18 years
• Eastern Cooperative Oncology Group (ECOG) status =< 2
• Histologically confirmed mature peripheral T-cell or natural killer (NK)-cell lymphoma per World Health Organization (WHO) classification, including: * Anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL) with international protein index (IPI) of 2 or higher (must have bulky [defined as mass >= 10 cm] stage II, or stage III-IV disease) * ALK-negative ALCL ** NOTE: Per amendment dated 05-10-19, ALCL will no longer be eligible except for Canada. * PTCL-not otherwise specified (NOS) * Angioimmunoblastic T-cell lymphoma (AITL) * Adult T-cell lymphoma/leukemia (ATLL) * Enteropathy-associated T-cell lymphoma (EATL) * Hepatosplenic T-cell lymphoma ** T-max cohort (added per protocol amendment V12, dated 05/22/23): Only non-ALCL subtypes (e.g. PTCL-NOS, AITL, ATLL, EATL, MEITL, intestinal T-cell lymphoma-NOS, HSTCL) are eligible
• CD30-positivity (e.g. at least 1%) by immunohistochemistry confirmed by hematopathology review at the participating institution
• Measurable disease of at least 1.5 cm on computed tomography (CT) or positron emission tomography (PET)-CT scan
• Absolute neutrophil count (ANC) >= 1,000/mm^3 * Exception: unless documented bone marrow involvement by lymphoma
• Platelets >= 50,000/mm^3 * Exception: unless documented bone marrow involvement by lymphoma
• Total serum bilirubin =< 1.5 x upper limit of normal (ULN) OR if hepatic involvement by lymphoma: =< 3 x ULN for Gilbert's disease or documented hepatic involvement by lymphoma
• Aspartate aminotransferase (AST) =< 2 x ULN OR if hepatic involvement by lymphoma: AST =< 5 x ULN
• Alanine aminotransferase (ALT) =< 2 x ULN OR if hepatic involvement by lymphoma: ALT =< 5 x ULN
• Creatinine clearance of >= 60 mL/min per the Cockcroft-Gault formula
• Left ventricular ejection fraction (LVEF) >= 45%
• Women of childbearing potential (WOCBP): negative urine or serum pregnancy test; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
• Agreement by WOCBP and males of childbearing potential to use an effective method of birth control or abstain from heterosexual activity for the course of the study through at least 6 months after the last dose of protocol therapy; childbearing potential defined as not being surgically sterilized (men and women) or have not been free from menses for > 1 year (women only)

Exclusion Criteria

• Prior treatment of PTCL with systemic anti-lymphoma therapies, investigational agents, radiation * Exception: May have received 1 cycle of CHOP-like therapy (e.g. CHOP, CHOEP, EPOCH) or 1 cycle of CHP-BV; these participants must initiate day 1 cycle 1 of study therapy (CHEP-BV) no less than 19 days from prior CHOP-like or CHP-BV therapy; Patients who received 1 cycle of CHOP‐like or 1 cycle of CHP-BV therapy prior to initiating induction with CHEP‐BV are allowed to receive only 5 cycles of CHEP-BV instead of 6 cycles, per investigator's discretion
• History of another primary invasive cancer, hematologic malignancy, or myelodysplastic syndrome that has not been in remission for at least 3 years. * Exceptions: Non-melanoma skin cancer and in situ cervical cancer
• Symptomatic cardiac disease (including symptomatic ventricular dysfunction, symptomatic coronary artery disease, and symptomatic arrhythmias), cerebrovascular event/stroke or myocardial infarction within the past 6 months
• Central nervous system involvement by lymphoma, including leptomeningeal involvement
• History of progressive multifocal leukoencephalopathy (PML)
• Active >= grade 3 viral, bacterial, or fungal infection within 2 weeks prior to day 1 of protocol therapy
• Any known human immunodeficiency virus (HIV) infection, hepatitis B surface antigen-positive status, or known or suspected active hepatitis C infection
• Baseline peripheral neuropathy >= grade 2 or patients with the demyelinating form of Charcot-Marie-Tooth syndrome
• Known severe hypersensitivity to any study related agent excipient(s)
• Females only: pregnant or breastfeeding
• Any other condition that would, in the investigator's judgement, contraindicate the patient's participation in the clinical study
• Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)